ETC-159 In Combination With Pembrolizumab In Advanced MSS/pMMR Ovarian Cancers
Status:
RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, investigator-initiated study conceived as a dose expansion cohort of the study D3-002, which evaluated ETC-159 in combination with pembrolizumab in solid tumors.
Phase:
PHASE1
Details
Lead Sponsor:
National University Hospital, Singapore
Collaborator:
EDDC (Experimental Drug Development Centre), A*STAR Research Entities